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Abstract
This paper describes the clinical course of a patient with chronic hepatitis C, genotype 2a/2c,
previously treated with Interferon α2b and subsequently with Lymphoblastoid Interferon without
any response, and also without any cutaneous side effects. The patient, a 50 year-old woman, was
re-treated with Pegylated α2b Interferon plus Ribavirin for 24 weeks, at standard doses; during the
third month of therapy she developed a mild form of psoriasis. However, encouraged by the
progressive improvement of her transaminase levels and viral load decrease, the patient asked to
continue the treatment; she normalized the transaminase levels during the fourth month and
showed HCV-RNA negativity during the fifth month of therapy. Nevertheless, the psoriasis
become worse, extending to over 75% of her body. Therapy was completed after sixth months. A
month after the therapy was ceased, the patient's psoriasis receded spontaneously and completely.
During the subsequent four years the patient did not experience any recurrence of either the
hepatic disease or the psoriasis.
Background
In patients suffering from chronic hepatitis C Interferon
(IFN) therapy can induce various side effects, especially of
autoimmune type; of these, thyroiditis, thrombocytope-
nia, systemic lupus erythematosus and rheumatoid arthri-
tis are the most frequent. A certain susceptibility for
immunologic abnormalities [1] plays a key role. Further
more, side effects can also occur involving the skin includ-
ing vasculitis, necrosis, ulceration, and alopecia [2,3].
Exacerbation of pre-existent psoriasis [3-6] and induction
of psoriasis have also been described [7].
Case presentation
A 50 year-old woman with HCV-related chronic hepatitis,
without history of psoriasis, had been previously treated
with 2 cycles of IFN: firstly she had received recombinant
IFN alpha α2b (Intron A®, Schering-Plough) 3 MU trice/
week for 36 weeks (September 1996–May 1997); then
Lymphoblastoid IFN (Wellferon®, Glaxo Wellcome) 3 MU
trice/week for 24 weeks (October 1997–March 1998). In
both cases there was no response, neither virological nor
serological. During these two courses of therapy, the
patient only suffered from minimal and transient side
effects. Since then, aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels were 1.5–2.5 times
above the upper limit of normality.
On admission in October 2001 the AST and ALT levels
were 54 and 97 U/L, respectively (normal value ≤ 40 U/l);
the platelets count was 179,000 mmc and hemoglobin
13.3 g/dL; HCV-RNA was positive (AxSYMHCV 3.0®
Abbott); the viral load was 560,000 IU (Cobas Amplicor
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HCV Monitor 2.0® Roche); the genotype was characterized
as 2a/2c (Genotype HCV III® Nuclear Laser, Milan, Italy).
ANA, AMA, SMA, Anti -TPO Ab and Anti-TG Ab were
absent; FT3, FT4 and TSH serum concentrations were
within the normal range. Liver biopsy, performed in the
1996 and repeated before the treatment, showed a mild
hepatitis (Knodell score 13–15/22; Metavir score A2 F2),
(Figure 1 and 2). The patient was re-treated with PEG IFN
α2b (Peg Intron®, Schering-Plough) 100 μg once a week,
plus Ribavirin (Rebetol®, Schering-Plough) 800 mg/day,
for 24 weeks. During the first three doses of Peg IFN the
patient suffered from typical self-limited flu-like syn-
drome, with fever (up to 39°C), arthro-myalgias and
asthenia. AST/ALT levels started lowering, i.e., 39/56 U/L
and 36/43 U/L at the second and third month, respec-
tively; by the middle of the third month, the HCV-RNA
load kept on decreasing until it was more than two LOGs
(3,500 IU) at the end of the fourth month of treatment.
At the beginning of the third month the patient developed
a mild form of plaque psoriasis; this comprised a few,
scarcely raised, thickened patches of red skin, covered
with silvery-white scales, which were present on the skin
surface of the knees, elbows, scalp and trunk, involving
less than 10% of the body surface area. The therapy was
continued, in accordance with the patient's firm request
and based on the encouraging results. The Beck Depres-
sion Inventory was performed, without showing evidence
of any mood disorders [8]. During the fourth month of
treatment, the patient's AST and ALT levels were normal-
ised (23 and 31 U/L, respectively); from then on, these
values were always normal. The serum HCV-RNA was neg-
ative at the fifth month of therapy; instead, psoriasis wors-
ened, becoming extensive (involving more than 75% of
the body surface area) and affecting the thorax, dorsum,
abdomen, arms, thighs, and legs (Figure 3 and 4). Joint
disease of psoriatic origin (criteria: either greater than two
swollen or two tender/painful joints for more than two
weeks) did not appear. In any case, the therapy was con-
tinued until the sixth month, at which time it was stopped
(April 2002), Figure 5.
After discontinuation of therapy, the psoriasis spontane-
ously receded, in a slow but complete fashion, within one
month, without any local or systemic therapy. From then
on, the patient underwent periodic check-ups which have
always showed a sustained response. At the time of publi-
cation, and after more than four years of follow-up, the
patient has not experienced relapse of either the hepatic
disease or the psoriasis.
Discussion
Extrahepatic manifestations and IFN-induced side-effects
sometimes overlap. Mixed cryoglobulinemia is the most
Extensive psoriasis: the body is involved in almost its entirety Figure 3
Extensive psoriasis: the body is involved in almost its 
entirety.
Conspicuous lymphocytic infiltration of portal tracts (Hema- toxylin & Eosin, 200 ×) Figure 1
Conspicuous lymphocytic infiltration of portal tracts (Hema-
toxylin & Eosin, 200 ×).
Porto-portal passive septa Figure 2
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studied syndrome associated with this infection. It is a sys-
temic vasculitis that may involve the skin, kidney and
nervous system. A frequent association is that between
HCV infection and non-Hodgkin lymphoma. Thyroid dis-
ease (hypothyroidism) is commonly seen in people with
hepatitis C. Other studies describe a correlation between
hepatitis C virus and lymphocytic sialoadenitis. Rheuma-
tologic symptoms such as polyarthritis often occur in peo-
ple with hepatitis C. Finally, hepatitis C infection has been
associated with dermatological disorders such as porphy-
ria cutanea tarda and lichen planus. An efficient cure for
hepatitis C infection, based on combined antiviral ther-
apy, is available. Side-effects such as flu-like syndrome,
depression, haemolytic anemia, cytopenia and alopecia
can limit its use.
The patient in this case had received two types of standard
IFN in the past, without virological effectiveness, but also
without any cutaneous involvement. Therapy with PEG
IFN plus Ribavirin led to a sustained response, but also an
extensive form of psoriasis. Many clinicians believe that
the onset of psoriasis during IFN therapy is an absolute
contraindication to its continuation.
In this case the IFN therapy was continued, without any
specific intervention for the psoriasis. This was because
the AST/ALT levels had improved since the second month
therapy, forecasting eradication of HCV especially in the
light of a favourable genotype, and spontaneous regres-
sion of the cutaneous manifestation was considered pos-
sible at the end of therapy cycle once the, trigger that had
generated it was withdrawn. The patient wished to com-
plete the therapy (at that time the normal duration of this
antiviral therapy combination was six months), as she was
very worried about the possible development of cirrhosis
and because she was seeing for the first time the levels of
AST/ALT diminishing. Moreover, she did not consider the
body appearance important. She had no evidence of a
mood disorder. This last point played a key role in rein-
forcing the physicians' decision to continue treatment.
A previous case study reported a 45-year-old woman with
chronic hepatitis C who was treated with the same antivi-
ral schedule and who developed psoriasis, after not hav-
ing experienced symptoms of the condition for the past 10
years. In that case the psoriatic lesions worsened dramati-
cally during therapy. Cutaneous lesions appeared at vari-
ous sites including the face, the back of the ears, the
breasts the anus and the elbows. Because of the severity of
the psoriatic disease, therapy was discontinued after 14
weeks from the treatment onset, when the serum RNA was
eliminated. The authors reporting that case [9] concluded
that this side effect should be kept in mind in the treat-
ment of patients with a history of psoriasis.
In this reported case the therapeutic interruption coin-
cided with viral clearance, but did not answer the question
of what is the best approach when viral clearance has not
yet been achieved.
Finally, we offer a comment on the pathogenesis of the
IFN-induced psoriasis in association with chronic hepati-
tis C. Psoriasis is considered a T cell-mediated disease,
with a strong cytokine component. Whereas pro-inflam-
matory cytokines such as tumor necrosis factor-alpha is
overexpressed in this diseases, a type 1 cytokine pattern
predominates. Recently [10] a case has been reported of a
Clinical, laboratory and therapeutical data Figure 5
Clinical, laboratory and therapeutical data.
Extensive psoriasis: involvement of trunk and lower limbs Figure 4
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patient with psoriasis and hepatitis C virus infection who
initially presented with psoriatic erythroderma and even-
tually showed complete clearance of psoriatic lesions fol-
lowing acute hepatitis induced by etretinate treatment.
Cytokine synthesis capabilities in peripheral blood T cells
showed a dramatic increase in the frequency of interferon-
gamma-producing CD8+ T cells. This process was
observed during the erythrodermic stage. In contrast, the
frequencies of interleukin (IL)-4- and IL-13-producing
CD4+ T and CD8+ T cells were remarkably high at the res-
olution stage. These results clearly indicate that a shift
towards type 2 cytokine predominance contributes to the
resolution of severe psoriasis. This interesting observation
is in accordance with data indicating that a T-helper (Th)
1 to Th2 shift does not occur in chronic hepatitis C. Fur-
ther more, IFN alpha alone or in combination with riba-
virin acts induces and maintains high rates of significant
CD4+ Th 1 response [11].
In conclusion, we acknowledge that no definitive guide-
lines exist concerning the clinical conduct in this specific
situation. Our clinical experience on a single case could
contribute to resolving this matter, as appropriate trials
are very difficult to implement for ethical reasons.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All the Authors equally participated in the preparation of
this case report on the basis of their expertise.
They read and approved the final manuscript.
Acknowledgements
The patient gave her written consent to publish this case-report.
References
1. Okamoue T, Itoh Y, Yasui K: Autoimmune disorders in inter-
feron therapy.  Nippon Rinsho 1994, 52:1924-8.
2. Parquet P, Pierand-Franchimont C, Arrese JE, Pierard GE: Cutane-
ous side effects of interferons.  Rev Med Liege 2001, 56:699-702.
3. Downs AM, Dunnil MG: Exacerbation of psoriasis byinterferon-
alpha therapy for Hepatitis C.  Clin Exp Dermatol 2000, 25:351-2.
4. Erkek E, Karaduman A, Akcan Y, Sokmensuer C, Bukulmez G: Pso-
riasis associated with HCV and exacerbated by interferonal-
pha: complete clearance with acitretin during interferon
alpha treatment for chronic active hepatitis.  Dermatology
2000, 201:179-81.
5. Makino Y, Tanaka H, Nakamura K, Fujita M, Akiyama K, Makino I:
Arthritis in a patient with psoriasis after interferon-alpha
therapy for chronic hepatitis C.  J Rheumathol 1994, 21:1771-2.
6. Matsuoka H, Uno H, Nakama N, Maeda K, Tsubouchi H: Psoriasis
exacerbated by alpha-interferon therapy in a case of chronic
myelogenous leukaemia.  Rinsho Ketsueki 1994, 35:309-11.
7. Taylor C, Burns DA, Wiselka MJ: Extensive psoriasis induced by
interferon alfa treatment for chronic hepatitis C.  Postgrad
Med J 2000, 6:365-7.
8. Golden J, Conroy RM, O'dwyer AM: Reliability and validity of the
Hospital Anxiety and Depression Scale and the) in detecting
depression in persons with hepatitis C.  J Affect Disord  in press.
2006 Dec 5
9. Kartal ED, Colak H, Ozgunes I, Usluer G: Exacerbation of psoria-
sis due to peginterferon alpha-2b plus ribavirin treatment of
chronic active hepatitis C.  Chemotherapy 2005, 51:167-9.
10. Kano Y, Teraki Y, Shiohara T: Dramatic improvement of psori-
atic erythroderma after acute hepatitis: analysis of cytokine
synthesis capability in peripheral blood T cells.  Br J Dermatol
2006, 155:455-9.
11. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW: Peginterferon
alone or with ribavirin enhances HCV-specific CD4 T-helper
1 responses in patients with chronic hepatitis C.  Gastroenterol-
ogy 2002, 123:1070-83.